-
Pramipexole
- indication:For the treatment of signs and symptoms of idiopathic Parkinson's disease
- pharmacologypharmacology:
- mechanism: The precise mechanism of action of Pramipexole as a treatment for Parkinson's disease is unknown, although it is believed to be related to its ability to stimulate dopamine receptors in the striatum.
- toxicity:
- absorprion: Rapid. Absolute bioavailability is greater than 90%, indicating that pramipexole is well absorbed and undergoes little presystemic metabolism. Food does not affect the extent of absorption.
- halflife: 8 hours
- roouteelimination: Urinary excretion is the major route of pramipexole elimination, with 90% of a pramipexole dose recovered in urine, almost all as unchanged drug. Nonrenal routes may contribute to a small extent to pramipexole elimination, although no metabolites have been identified in plasma or urine.
- volumedistribution: * 500 L
- clearance: * renal cl=400 mL/min